Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 804 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... April 24, 2019 FDA Approvals Bring New Options for Older Patients with AML December 27, 2018 Cancer in My Community: Reducing Tobacco Use in Tunisia December 8, 2022 Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... April 15, 2024 Load more HOT NEWS Airbrushed Magazines Hurt the Body Image of Young Women — Here’s... 6 Habits That Can Help You Feel More in Control of... Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... Survivorship and Immune Checkpoint Inhibitors
